Monte Rosa Therapeutics, Inc.
GLUE Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$10.84
KIRA · Stoqly’s AI analyst, in plain words
- Monte Rosa Therapeutics, Inc. had $124M of revenue in fiscal 2025, up 63.5% on the year before.
- Its operating margin was −43.8%, up 63.4 pts: of every 100 in sales, about −44 is left after running the business.
- Monte Rosa Therapeutics, Inc. lost $38.6M in fiscal 2025.
- Free cash flow was −$27.5M in fiscal 2025, −22.2% of revenue.
- Monte Rosa Therapeutics, Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 12.4%.
Market cap
$1.1B
P/E
—
Revenue
$124M
Net income
−$38.6M
Free cash flow
−$27.5M
Operating margin
−43.8%
Monte Rosa Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+63.5%
Yes. Sales grew 63.5% last year.
Does it make a profit?
−31.2%
No. It lost money last year.
Does profit turn into cash?
−22.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
What Monte Rosa Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 17, 2026
- Legal name
- Monte Rosa Therapeutics, Inc.
- CIK
- 0001826457
Monte Rosa Therapeutics, Inc. · GLUE
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | $0.0M | $75.6M | $124M |
| Revenue growth | — | — | — | — | 63.5% |
| Operating margin | — | — | — | −107.3% | −43.8% |
| Net income | −$74.0M | −$109M | −$135M | −$72.7M | −$38.6M |
| Net margin | — | — | — | −96.1% | −31.2% |
| Diluted EPS | −$2.96 | — | — | — | — |
| Cash | |||||
| Cash from operations | −$59.4M | −$92.5M | −$43.8M | $42.0M | −$22.8M |
| Capital expenditure | $9.7M | $12.9M | $19.0M | $4.0M | $4.7M |
| Free cash flow | −$69.1M | −$105M | −$62.8M | $38.0M | −$27.5M |
| FCF margin | — | — | — | 50.3% | −22.2% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share count change | 1,548.1% | 88.9% | 8.8% | 43.8% | 12.4% |
| Debt and strength | |||||
| Cash and short-term investments | $346M | $54.9M | $128M | $224M | $130M |
| Shareholders' equity | $348M | $271M | $179M | $223M | $233M |
| Current ratio | 21.0x | 10.8x | 5.1x | 2.4x | 6.1x |
| Returns and quality | |||||
| Return on equity | −49.5% | −35.1% | −60.1% | −36.2% | −16.9% |
| Return on tangible equity | −21.3% | −40.0% | −75.5% | −32.6% | −16.6% |
| Piotroski F-score | — | — | — | 4 | 4 |
| Altman Z'' | 22.9 | 4.4 | −1.5 | −0.1 | 1.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$4.1M
8 insiders
Of sales under plans
54%
$2.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Monte Rosa Therapeutics, Inc. · GLUE
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $10.84 a share, the company is worth $1.1B.
Source: SEC EDGAR XBRL filings (CIK 0001826457). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.